1-3 of 3
Yali Zhou
Close
Sort by
Journal Articles

Safety and Efficacy of RM-001 (Autologous HBG1/2 Promoter-modified CD34+ Hematopoietic Stem and Progenitor Cells) in Patients with Transfusion-Dependent β-Thalassemia

Rongrong Liu, Li Wang, Hui Xu, Xiaolin Yin, Junbin Liang, Wenqiang Xie, Gaohui Yang, Yaoyun Li, Yali Zhou, Lei Shi, Bin Xiao, Lingling Shi, Zeyan Shi, Xuemei Zhou, Xiangmin Xu, Jianpei Fang, Yongrong Lai, Junjiu Huang, Xinhua Zhang
Journal: Blood
Blood (2023) 142 (Supplement 1): 4994.
https://doi.org/10.1182/blood-2023-181453
Published: 2023
Journal Articles

A Novel Universal CD7-Targeted CAR-T Cell Therapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia and T-Cell Lymphoblastic Lymphoma

Xian Zhang, Yali Zhou, Junfang Yang, Jingjing Li, Liyuan Qiu, Wengang Ge, Bo Pei, Jie Chen, Lu Han, Jiangtao Ren, Peihua Lu
Journal: Blood
Blood (2022) 140 (Supplement 1): 4566–4567.
https://doi.org/10.1182/blood-2022-165733
Published: 2022
Journal Articles

The Safety and Efficacy of a CRISPR/Cas9-Engineered Universal CAR-T Cell Product (CTA101) in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Yongxian Hu, MD, Yali Zhou, Mingming Zhang, MD, Wengang Ge, Yi Li, MD, Li Yang, MD, Guoqing Wei, MD, Lu Han, Hao Wang, Xingwang Zhang, PhD, Jiangtao Ren, PhD, He Huang, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 52.
https://doi.org/10.1182/blood-2020-142262
Published: 2020